Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of Artavol versus dihydroartemisinin + piperaquine for malaria prophylaxis and treatment in Ugandan schoolchildren
PACTR202507671739176Phase 2Not yet recruiting
- Sponsor
- Science Technology and Innovation Secretariat
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dihydroartemisinin + piperaquine in malaria (2 arms), sponsored by Science Technology and Innovation Secretariat. Primary endpoints: Incidence of malaria parasitaemia and Incidence of clinical malaria. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
dihydroartemisinin + piperaquine
03
Conditions
malaria
Beyond the preview
Go deeper on PACTR202507671739176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202507671739176.